BCL2L1 is a paradigm case of antagonistic isoform functions in alternative splicing.
| Isoform |
UniProt ID |
Function |
Mechanism |
| Bcl-X(L) |
Q07817-1 |
Anti-apoptotic |
Inhibits caspases, blocks VDAC, prevents CYC1 release |
| Bcl-X(S) |
Q07817-2 |
Pro-apoptotic |
Promotes apoptosis (lacks BH1/BH2 domains) |
| Bcl-X(beta) |
Q07817-3 |
Unknown |
Third isoform, less studied |
Tissue Distribution
- Bcl-X(S): High in cells with high turnover (developing lymphocytes)
- Bcl-X(L): High in long-lived postmitotic cells (adult brain)
Domain Structure Differences
- Bcl-X(L): Contains BH1, BH2, BH3, BH4 domains
- Bcl-X(S): Lacks BH1 and BH2 domains (alternative 5' splice site in exon 2)
- The BH4 motif is required for anti-apoptotic activity
- BH1/BH2 are required for heterodimerization with other Bcl-2 family members
Problem: Conflated GO Annotations
The current GOA file has 157 annotations but NO isoform-specific annotations (no Q07817-1 or Q07817-2).
Conflicting Annotations Identified
Pro-apoptotic annotations (likely Bcl-X(S)):
- GO:0043065 "positive regulation of apoptotic process" - IBA
Anti-apoptotic annotations (likely Bcl-X(L)):
- GO:0043066 "negative regulation of apoptotic process" - IDA (multiple PMIDs)
- GO:1902236 "negative regulation of ER stress-induced intrinsic apoptotic signaling pathway" - IDA
- GO:1902042 "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors" - IDA
- GO:1902230 "negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage" - IDA
- GO:2001240 "negative regulation of extrinsic apoptotic signaling pathway in absence of ligand" - TAS
- GO:1900118 "negative regulation of execution phase of apoptosis" - IDA
- GO:2001243 "negative regulation of intrinsic apoptotic signaling pathway" - IDA
The Core Issue
When you see both "positive regulation of apoptosis" AND "negative regulation of apoptosis" for the same gene, this is usually a sign of:
1. Isoform conflation (this case)
2. Context-dependent functions
3. Cleaved vs full-length protein (BCL2L1 also has this - caspase cleavage removes BH4, converting anti-apoptotic to pro-apoptotic)
Key References
Original Discovery
- PMID:8358789 - Boise et al. 1993 "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death"
- Describes both Bcl-X(L) and Bcl-X(S) isoforms
- Shows Bcl-X(L) inhibits apoptosis; Bcl-X(S) promotes it
- PMID:9675101 - Ban et al. 1998 "Identification of a human cDNA encoding a novel Bcl-x isoform"
Review Strategy
- Annotations with IDA evidence: Check which isoform was actually used in experiments
- IBA annotation to GO:0043065: This may incorrectly infer pro-apoptotic function from paralogs
- IEA annotations: These are automated and likely conflate isoforms
- Consider proposing isoform-specific annotations with reference to Q07817-1 and Q07817-2
Cancer Relevance
- Bcl-X(L) overexpression confers drug resistance in cancer
- Bcl-X(L) is a therapeutic target (BH3 mimetics like navitoclax)
- Splicing factor mutations can shift the Bcl-xL/Bcl-xS ratio
Questions for Review
- Are there any papers that specifically tested Bcl-X(S)?
- Should the IBA annotation to GO:0043065 be REMOVED since it may not apply to the canonical isoform?
- Which isoform was used in each IDA experiment?